Anyone understanding what is going on with this stock?
The same thing that's going on with every other speculative biotech. Just looking at the As, Avexa and Acrux have performed similarly.
(I rank Alchemia in between those two as far as risk goes. Acrux, with one product already selling and others not far off, is less risky. But Alchemia's lead drug is a synthetic generic which should see rapid approval, where Avexa is still in Phase III trials; Alchemia also has a partner while Avexa is looking for one.)
A back of the envelope calculation: Arixtra sales $300m/year, likely share of that taken by generic $100m/year, profits on that $50m/year, Alchemia's share of those $25m/year.
Obviously there's concern about the delay filing the ANDA. If they can't get the manufacturing to scale to commercial volumes, that would be a killer.
- Forums
- ASX - By Stock
- TSN
- free fall
free fall, page-4
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add TSN (ASX) to my watchlist
(20min delay)
|
|||||
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.409M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
TSN (ASX) Chart |
Day chart unavailable
The Watchlist
BM8
BATTERY AGE MINERALS LTD
Nigel Broomham, CEO
Nigel Broomham
CEO
Previous Video
Next Video
SPONSORED BY The Market Online